Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.

Hervás A, Pastor J, González C, Jové J, Gómez A, Casaña M, Villafranca E, Mengual JL, Muñoz V, Henriquez I, Muñoz J, Collado E, Clemente J.

Clin Transl Oncol. 2018 Dec 10. doi: 10.1007/s12094-018-02000-y. [Epub ahead of print]

PMID:
30536208
2.

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.

Bracci S, Osti MF, Agolli L, Bertaccini L, De Sanctis V, Valeriani M.

Radiat Oncol. 2016 Jun 8;11:78. doi: 10.1186/s13014-016-0656-0.

3.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
4.

High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.

Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1473-9. doi: 10.1016/j.ijrobp.2011.10.036. Epub 2012 Jan 13.

PMID:
22245201
5.

External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.

Boladeras A, Santorsa L, Gutierrez C, Martinez E, Pera J, Pino F, Suarez JF, Ferrer F, Díaz A, Polo A, Guedea F.

Radiother Oncol. 2014 Aug;112(2):227-32. doi: 10.1016/j.radonc.2014.07.013. Epub 2014 Aug 28.

PMID:
25174299
6.

Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.

Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D.

Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395.

7.

Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.

Hervás A, Gómez-Caamaño A, Casaña M, Gómez-Iturriaga A, Pastor J, Jove J, Mengual JL, Gónzalez-San Segundo C, Muñoz J.

Clin Transl Oncol. 2018 Feb;20(2):193-200. doi: 10.1007/s12094-017-1709-z. Epub 2017 Jun 30.

PMID:
28667448
8.

Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z.

BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3.

9.

The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.

Can J Urol. 2017 Feb;24(1):8656-8662.

PMID:
28263132
10.

Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.

Naik M, Reddy CA, Stephans KL, Ciezki JP, Garcia J, Grivas P, Stephenson AJ, Klein EA, Tendulkar RD.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):617-23. doi: 10.1016/j.ijrobp.2016.07.009. Epub 2016 Jul 17.

PMID:
27681757
11.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
12.

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33.

PMID:
14697417
13.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

14.

Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiotherapy for localized prostate cancer.

Abu-Gheida I, Reddy CA, Kotecha R, Weller MA, Shah C, Kupelian PA, Mian O, Ciezki JP, Stephans KL, Tendulkar RD.

Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30182-8. doi: 10.1016/j.ijrobp.2019.01.091. [Epub ahead of print]

PMID:
30721720
15.

PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.

Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50. Epub 2005 Sep 29.

PMID:
16198506
16.

Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.

Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA.

Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):567-74.

PMID:
10701735
17.

Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.

Tendulkar RD, Reddy CA, Stephans KL, Ciezki JP, Klein EA, Mahadevan A, Kupelian PA.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404. doi: 10.1016/j.ijrobp.2011.04.042. Epub 2011 Jun 12.

PMID:
21665379
18.

CLINICAL OUTCOMES OF EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH NEOADJUVANT ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK PROSTATE CANCER.

Okada T, Takayama K, Kokubo M, Kono Y, Matsumoto K, Sumiyoshi T, Masuda N, Shiraishi Y, Negoro H, Utsunomiya N, Tsunemori H, Okubo K, Segawa T, Moroi S, Muguruma K, Kawakita M.

Nihon Hinyokika Gakkai Zasshi. 2016;107(3):162-169. doi: 10.5980/jpnjurol.107.162. Japanese.

19.
20.

Supplemental Content

Support Center